Monte Rosa Therapeutics Inc. (GLUE) is a clinical-stage biotechnology company advancing a portfolio of molecular glue degraders (MGDs), a novel class of small molecules designed to harness the body's natural protein degradation pathways.
With three programs in clinical development, strategic collaborations with Novartis and Roche, and a proprietary discovery engine known as QuEEN (Quantitative and Engineered Elimination of Neosubstrates), the company is attempting to redefine therapeutic possibilities across oncology, immunology, and inflammation.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.